Cefotetan Disodium
FDA-approved product (injectable, injection), marketed as Cefotan, Cefotan In Plastic Container, Cefotetan and 1 more.
- Registered studies
- 7
- Lab records
- 2
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Second-generation cephalosporins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DC05
Repurposing investigation
Cefotetan Disodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli85.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae93.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
7registered studies name this medicine, for any condition. See them below.
Experimental
- E. coli: measured active in 1 of 1 lab record
- K. pneumoniae: measured active in 1 of 1 lab record
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cefotetan Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Cefotetan Therapy for Escherichia Coli Infections
NCT07318584 · start 2026-03
Registered record
- Registry ID
- NCT07318584
- Conditions
- E Coli Infection; ESBL Producing E.Coli
- Interventions
- Cefotetan; Carbapenems; Beta Lactam Antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-03
- Completion
- 2028-08
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionE Coli Infection; ESBL Producing E.ColiInterventionCefotetan; Carbapenems; Beta Lactam AntibioticsPhasePhase 2Registry statusNot yet recruitingEffectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
NCT04726046 · start 2014-04-01
Registered record
- Registry ID
- NCT04726046
- Conditions
- Cholecystitis
- Interventions
- Cefotetan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-04-01
- Completion
- 2017-09-25
- Enrolment
- 529
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCholecystitisInterventionCefotetanPhasePhase 1Registry statusCompletedPatients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminatedSafety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery
NCT01220661 · start 2010-10
Registered record
- Registry ID
- NCT01220661
- Conditions
- Colorectal Surgery
- Interventions
- Cefotetan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2011-12
- Enrolment
- 312
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal SurgeryInterventionCefotetanPhasePhase 2Registry statusCompletedArthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA)
NCT01204606 · start 2010-09
Registered record
- Registry ID
- NCT01204606
- Conditions
- Rotator Cuff Tear
- Interventions
- Arthroscopic rotator cuff repair with intraoperative periarticular injection; Arthroscopic rotator cuff repair with non-injection of MMA drugs
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-09
- Completion
- Not recorded
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRotator Cuff TearInterventionArthroscopic rotator cuff repair with intraoperative periarticular injection; Arthroscopic rotator cuff repair with non-injection of MMA drugsPhaseNot applicableRegistry statusCompletedAntibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs
NCT00186082 · start 2003-09
Registered record
- Registry ID
- NCT00186082
- Conditions
- Pregnancy Complications, Infectious
- Interventions
- Cefotetan or Cefoxitin vs placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2008-06
- Enrolment
- 147
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPregnancy Complications, InfectiousInterventionCefotetan or Cefoxitin vs placeboPhaseNot applicableRegistry statusCompletedA Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)
NCT00090272 · start 2002-04
Registered record
- Registry ID
- NCT00090272
- Conditions
- Colorectal Surgery
- Interventions
- MK0826, ertapenem sodium; Comparator: cefotetan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-04
- Completion
- 2005-03
- Enrolment
- 952
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal SurgeryInterventionMK0826, ertapenem sodium; Comparator: cefotetanPhasePhase 3Registry statusCompleted